From the Journals

Study: No link between non-Hodgkin lymphoma and Q fever


 

FROM LANCET HAEMATOLOGY

There appears to be no causal link between acute Q fever and the development of non-Hodgkin lymphoma, according to findings from a retrospective analysis of 12 years of Dutch data.

Sonja E. van Roeden, MD, and colleagues from Utrecht University, the Netherlands, performed a retrospective, population-based analysis of the entire general population of the Netherlands from 2002 to 2013, encompassing the 3-year period of a large Q fever epidemic in the country.

National Institutes of Health (NIH)/Wikimedia Commons
The researchers were prompted to investigate the connection between exposure to Coxiella burnetii – the causative agent in Q fever – and non-Hodgkin lymphoma (NHL) after a 2016 French study showed increased incidence of NHL after infection with C. burnetii. In the current study, published in the Lancet Haematology, the researchers calculated the relative risks of NHL during 1-year periods before, during, and after the 2007-2010 Q fever epidemic. They also calculated the relative risks of NHL in individuals with chronic Q fever, compared with the general population.

In total, there were 48,760 cases of NHL diagnosed between Jan. 1, 2002 and Dec. 31, 2013, with the annual incidence ranging from 21.4 cases per 100,000 population in 2002 to 26.7 in 2010. While researchers found a significant association between NHL incidence and areas of high endemicity of Q fever in 2009 (relative risk 1.16; P = .029), there were no other associations.

Among the 439 people with chronic Q fever, 5 went on to develop NHL, resulting in a relative risk of 4.99 (P = .0003), compared with the general population of the Netherlands.

“The absence of an exposure-response relation between the intensity of exposure and risk of non-Hodgkin lymphoma, based on reported incidence of acute Q fever, does not imply a causal relation,” the researchers wrote. “However, one could consider exposure to C. burnetii in people with chronic Q fever as more intense than in acute Q fever because of the ongoing character and duration of exposure, and assume an exposure-response relation on the basis of the higher risk for non-Hodgkin lymphoma in patients with chronic Q fever.”

The researchers reported having no financial disclosures.

SOURCE: van Roeden SE et al. Lancet Haematol. 2018 May;5:e211-9.

Recommended Reading

Five-year survival for non-Hodgkin lymphoma tops 71%
MDedge Hematology and Oncology
Novartis CAR T-cell therapy adds a lymphoma indication
MDedge Hematology and Oncology
‘Long-term benefits’ with nivolumab in cHL
MDedge Hematology and Oncology
Drug granted fast track designations for FL, DLBCL
MDedge Hematology and Oncology
FDA issues CRL for proposed biosimilar rituximab
MDedge Hematology and Oncology
FDA approves CAR T-cell therapy for lymphoma
MDedge Hematology and Oncology
Predicting response to CAR T-cell therapy in CLL
MDedge Hematology and Oncology
Team identifies 5 subtypes of DLBCL
MDedge Hematology and Oncology
CHMP recommends approval for generic carmustine
MDedge Hematology and Oncology
Radioimmunoconjugate shows activity in NHL
MDedge Hematology and Oncology